Recursion Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Recursion Pharmaceuticals (RXRX).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

3Buy

4Hold

Consensus RatingOverweight# Analysts7Avg. Consensus PT$8Upside to Avg. PT+94.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 19, 2026	Needham	Gil Blum	Maintained	Buy	$8
May 14, 2026	Morgan Stanley	Vikram Purohit	PT Raise	Equal-Weight	$5→$6
May 7, 2026	Needham	Gil Blum	Maintained	Buy	$8
Apr 30, 2026	JP Morgan	Priyanka Grover	PT Cut	Overweight	$11→$10
Feb 26, 2026	B of A Securities	Michael Ryskin	PT Cut	Neutral	$7→$6
Feb 26, 2026	Needham	Gil Blum	Maintained	Buy	$8
Dec 17, 2025	JP Morgan	Eric Joseph	Upgrade	Neutral→Overweight	$10→$11
Sep 11, 2025	Needham	Gil Blum	Maintained	Buy	$8
Jul 8, 2025	Needham	Gil Blum	Maintained	Buy	$8
Jul 3, 2025	Morgan Stanley	Vikram Purohit	Assumes	Equal-Weight	$5
Jun 16, 2025	Morgan Stanley	Vikram Purohit	PT Cut	Equal-Weight	$8→$5
May 6, 2025	Needham	Gil Blum	PT Cut	Buy	$11→$8
Apr 10, 2025	Morgan Stanley	Vikram Purohit	PT Cut	Equal-Weight	$10→$8
Apr 8, 2025	Needham	Gil Blum	Maintained	Buy	$11
Feb 28, 2025	Leerink Partners	Mani Foroohar	PT Cut	Market Perform	$7→$6
Feb 6, 2025	Needham	Gil Blum	Maintained	Buy	$11
Jan 8, 2025	Keybanc	Scott Schoenhaus	PT Cut	Overweight	$12→$10
Dec 11, 2024	Needham	Gil Blum	Maintained	Buy	$11
Nov 20, 2024	Needham	Gil Blum	Maintained	Buy	$11
Nov 7, 2024	Needham	Gil Blum	Maintained	Buy	$11

Analyst Ratings News

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5

Morgan Stanley analyst Vikram Purohit maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Equal-Weight and raises the price target from $5 to $5.5.

Benzinga Newsdesk

Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back

Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.

Priya Nigam

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $10

JP Morgan analyst Priyanka Grover maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight and lowers the price target from $11 to $10.

Benzinga Newsdesk

PRO
B of A Securities Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $6

B of A Securities analyst Michael Ryskin maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Neutral and lowers the price target from $7 to $6.

Benzinga Newsdesk

Recursion Pharmaceuticals Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Recursion Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

PRO
Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5

Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

PRO
JP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $10

PRO
B of A Securities Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $6

People Also Watch

People Also Watch

Recursion Pharmaceuticals Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Recursion Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRONeedham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

PROMorgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5

Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back

PRONeedham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

PROJP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $10

PROB of A Securities Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $6

People Also Watch

People Also Watch

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

PRO
Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5

PRO
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

PRO
JP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $10

PRO
B of A Securities Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $6